LAKE FOREST, Calif., Sept. 18 /PRNewswire/ -- Worldwide markets of approved EGFr/HEr2 inhibitors grew by 34.2% during the first half of 2007, pushing sales to more than $3.2 billion, exceeding total sales reported in 2005. Hundreds of clinical trials are ongoing, aimed at expanding indications for these drugs and fueling continued rapid market growth. In addition to the seven marketed ErbB-pathway inhibitors, more than 50 novel agents targeting this pathway are in development.
"The ErbB Pathway in Cancer" is a series of comprehensive reports published in Future Oncology, New Medicine's premiere newsletter. Future Oncology provides analysis of critical issues in global cancer R&D, clinical practices, markets, and business and company developments. The series covers every aspect of the EGFr/HEr2 inhibitor marketplace, including:
-- Markets (USA and ROW) of approved drugs and forecasts
-- Treatment costs in the USA and ROW
-- Detailed ErbB pathway analyses
-- Associations of ErbB expression and mutations with specific indications
-- EGFr/HEr2-based diagnostic/theragnostic technologies and products
-- Detailed profiles of currently approved drugs
-- Comprehensive reviews of current use of approved drugs by indication
-- Comprehensive reviews of new indications of approved drugs
-- Protocols and interim and final results from clinical trials combining
approved ErbB pathway inhibitors with novel agents.
-- Detailed profiles of over 50 agents in development targeting the ErbB
pathway, including protocols and interim and final results from
hundreds of trials
This series, published in 5 parts, is available for purchase in electronic PDF or hard copy format.
|SOURCE New Medicine|
Copyright©2007 PR Newswire.
All rights reserved